How might advances in our understanding of the complement system lead to new therapeutic strategies beyond C5 inhibition?

Drug-induced liver injury (DILI), a rare, but potentially life-threatening drug reaction with elevated liver enzymes that may lead to liver failure or a need ... Jan 7, 2022 ... Soliris® (eculizumab) is the first medication to be approved by the Australian Therapeutic Goods Administration (TGA) for the treatment of an MS ... See full prescribing information for Soliris. Soliris™ (eculizumab),. Concentrated solution for intravenous infusion. Initial U.S. Approval: 2007. WARNING: ... Jul 27, 2023 ... Soliris (eculizumab) has been approved in the European Union (EU) for expanded use to include the treatment of refractory generalised myasthenia ... Develop highly selective and sensitive PK and ADA assays for the monoclonal antibody drug eculizumab (Soliris) using ready-made anti-idiotypic antibodies. NMOSD patients receiving Soliris should be monitored for early signs of meningococcal infection. No ongoing monitoring is recommended following discontinuation ... Aug 24, 2023 ... Pioneering treatment highly effective for rare kidney disease ... A pioneering drug for a rare kidney disease prevents organ failure and ... Soliris 300 mg concentrate for solution for infusion. Active Ingredient: eculizumab. Company: Alexion Pharma UK Ltd. See contact details. Sep 13, 2024 ... Soliris (eculizumab) is a prescription drug that's used to treat certain rare autoimmune conditions. Soliris is given as an intravenous (IV) infusion by a ... Mar 18, 2025 ... How is Soliris administered in myasthenia gravis? · 900 mg weekly for the first four weeks · 1,200 mg in the fifth week · 1,200 mg every other ...